Ostia Sciences Inc., a Toronto, Canada-based microbiome therapeutics firm creating next-generation probiotics, closed its seed financing spherical, elevating CAD $1.46m as of December 31, 2024.
Along with non-public funding, Ostia secured over $393k in non-dilutive grants, together with $350k from Pure Merchandise Canada (NPC) by way of its Proof-of-Idea (POC) program.
The NPC POC funding will assist advance Ostia’s deliberate scientific trials, specializing in pure options for widespread situations like gingivitis, halitosis, and treatment-related oral problems of head and neck most cancers sufferers.
Led by Dr. Abdelahhad Barbour, CEO, and Dr. Michael Glogauer, Chief Scientific Officer, Ostia Sciences is advancing phosphorylated lantibiotic-producing probiotic expertise for microbiome-based well being options to enhance oral well being and the standard of lifetime of hundreds of thousands of sufferers around the globe.
FinSMEs
20/07/2025
